Clinical trials: Vaccination
HIV INFECTIONS
Immunization With HIV-1 Peptides in Adjuvant for Treatment of Patients With Chronic HIV-infection
Treatment: Immunization with a peptide-mix of 17 Clusters of Differentiation number 8 (CD8) T cell minimal epitopes and 3 Clusters of Differentiation number 4 (CD4) T cell epitopes and a new adjuvant (CAF01).
- Trial name
- HIV-VAC (NCT01009762)
- Testing
- peptide vaccine (AFO-18)
- Where
- Denmark
- Volunteers
- 11 people
- Sponsor
- Gitte Kronborg
Vaccines, Pneumococcal
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine paediatric vaccines in…
- Trial name
- NCT00384059
- Testing
- 13-valent Pneumococcal Conjugate Vaccine, 7vPnC, Pediacel
- Where
- 11 sites in United Kingdom
- Volunteers
- 286 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
HIV Infection
Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals
The overall goal of this study is to compare the safety and immunogenicity of trivalent Fluzone® High-Dose vaccine vs the regular standard-dose (SD) in HIV infected individuals.
- Trial name
- NCT01262846
- Testing
- Fluzone®
- Where
- United States
- Volunteers
- 195 people
- Sponsor
- University of Pennsylvania
Infections, Rotavirus
Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Infants
This Post Marketing Surveillance (PMS) will collect reactogenicity and safety data on the use of human rotavirus vaccine in healthy infants aged from 6 weeks (first dose) to not more than 24 weeks (second dose).
- Trial name
- NCT00779779
- Testing
- Rotarix™
- Where
- Sri Lanka
- Volunteers
- 522 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papillomavirus Vaccines
Increasing Optimal Use of HPV Vaccination in Primary Care
Washington University will evaluate the effectiveness of a multi-component implementation strategy to increase use of HPV vaccine in primary care practices.
- Trial name
- NCT04180462
- Testing
- Practice Facilitation, Education, Audit and Feedback
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Varicella
Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM).
This study aims to assess the immunogenicity and safety of varicella vaccination in a population of autologous peripheral stem cell/ bone marrow transplantation recipients who have reached at least four months…
- Trial name
- NCT00792623
- Testing
- VarilrixTM
- Where
- 3 sites in Australia
- Volunteers
- 45 people
- Sponsor
- GlaxoSmithKline
Gastroenteritis
Efficacy and Safety of Two Doses of HIL-214 in Children
This is a randomized, placebo-controlled study that is being done to evaluate the safety and effectiveness of two doses of the HIL-214 vaccine compared to a placebo.
- Trial name
- NCT05281094
- Testing
- HIL-214
- Where
- 17 sites in United States, Colombia and 5 more
- Volunteers
- 3,084 people, healthy volunteers welcome
- Sponsor
- HilleVax
Safety, Adverse Event Following Immunisation
Safety of RIV4 Versus IIV4 in Pregnant Women
This is a prospective, randomized clinical trial. During the study, pregnant women will be randomized (1:1) to receive RIV4 or IIV4. Vaccines will be administered by licensed providers.
- Conditions
- Safety, Adverse Event Following Immunisation, Birth Outcomes
- Trial name
- NCT03969641
- Testing
- Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccine
- Where
- 3 sites in United States
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- Duke University
Meningococcal Immunisation (Healthy Volunteers)
Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)
Primary Objective: To demonstrate the vaccine seroresponse sufficiency of meningococcal serogroups A, C, Y, and W following the administration of a booster dose of meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus…
- Trial name
- NCT04084769
- Testing
- Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine, Meningococcal Group B vaccine (Trumenba®), Meningococcal group B vaccine (Bexsero®)
- Where
- 30 sites in United States, Puerto Rico
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Hepatitis B
Effectiveness of Two Hepatitis B Vaccines in HIV-negative Youths
This study will evaluate 2 licensed vaccine products (Recombivax and Twinrix) given in a two-dose schedule to youth at risk for hepatitis B and HIV infection to evaluate immunogenicity of the products in this population, barriers…
- Trial name
- NCT00107042
- Testing
- Recombivax, Twinrix
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Human Papillomavirus Infection
Communication Strategy to PROMOTE HPV Vaccination in Pharmacies: PROMOTE Study
This trial investigates how a communication strategy works in increasing human papillomavirus (HPV) vaccines in community pharmacies among adolescents.
- Trial name
- PROMOTE (NCT04660331)
- Testing
- Communication Intervention, Communication Skills Training, Healthcare Activity
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Health Behavior, Health Care Utilization
RADx-UP Phase 3D (Oregon Saludable: Juntos Podemos)
The ongoing Oregon Saludable: Juntos Podemos (OSJP, Healthy Oregon: Together We Can) project was developed to directly address the COVID-19 related health disparities among Latinx communities through community engagement funded…
- Conditions
- Health Behavior, Health Care Utilization, Vaccine Hesitancy
- Trial name
- NCT05910879
- Testing
- Self-Affirmation Implementation Intentions (SAII) Intervention, Promotores de Salud (Health Education)
- Where
- United States
- Volunteers
- 625 people
- Sponsor
- University of Oregon
Acellular Pertussis, Poliomyelitis
Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults
This study will evaluate the persistence of immune response against diphtheria, tetanus, pertussis and poliomyelitis in healthy adults, 10 years after a booster dose, and also assess the immunogenicity and safety of another…
- Conditions
- Acellular Pertussis, Poliomyelitis, Diphtheria, Tetanus
- Trial name
- NCT01323959
- Testing
- BoostrixTM Polio
- Where
- 15 sites in France, Germany
- Volunteers
- 212 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pneumococcal Disease
Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination
This Phase 3 will describe the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine formulation in adults 65 years of age or older with prior pneumococcal vaccination
- Trial name
- NCT03835975
- Testing
- 13vPnC, PPSV23, 20vPnC
- Where
- 42 sites in United States, Sweden
- Volunteers
- 875 people, healthy volunteers welcome
- Sponsor
- Pfizer
Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer
Some cancers may be related to an infection with a virus, such as the Human Papilloma Virus (HPV). HPV related Oropharyngeal cancer (HPVOPC) accounts for 80% of oropharynx cancer cases in the United States.
- Conditions
- Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT02002182
- Testing
- ADXS11-001 (ADXS-HPV)
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Andrew Sikora
Influenza
Evaluate Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults
Since influenza vaccines are administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profile of GSK Biologicals' influenza vaccine GSK576389A will be re-evaluated after…
- Trial name
- NCT00538473
- Testing
- GSK Biologicals' influenza vaccine GSK576389A, Fluarix™
- Where
- Belgium
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
GARDASIL Vaccination
Innovative Tool to Increase Completion of Human Papillomavirus (HPV) Vaccine Series
Planned Parenthood Federation of America's (PPFA) Medical Affairs Division will conduct a prospective, cluster randomized trial to determine which factors influence the acquisition of the second and third human papillomavirus…
- Trial name
- NCT01343485
- Testing
- Computer reminder system
- Where
- 9 sites in United States
- Volunteers
- 365 people, healthy volunteers welcome
- Sponsor
- Planned Parenthood Federation of America
Children, Pain
Emla-Cream as Pain Relief During Pneumococcal Vaccination
The aim of this intervention study is to compare the efficacy of Emla cream as a pain relief or no pain relief in connection to the first pneumococcal vaccination at the age of three months in Child health care.
- Trial name
- NCT01802086
- Testing
- Emla-cream, Miniderm cream
- Where
- Sweden
- Volunteers
- 72 people
- Sponsor
- Beatrice Olsson Duse
Rabies
Simplifying the Rabies Pre-exposure Vaccination
Rabies is a viral zoonosis that causes an encephalitis, almost invariably fatal. It is widely distributed across the globe: the World Health Organization (WHO) estimates that about 2,4 billion people live in endemic areas for…
- Trial name
- NCT01388985
- Testing
- Human Diploid Cell Vaccine (HDCV) rabies vaccine
- Where
- Belgium
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Influenza Immunization, Healthy Volunteers
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
This was a phase IV, multi-center, open-label study. The study collected serum samples from children 6 months to less than (<) 9 years of age who received Fluzone Quadrivalent vaccine and adults greater than or equal to (>=) 65…
- Trial name
- NCT05050318
- Testing
- Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation
- Where
- 2 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company